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BACKGROUND: Hypoxia, which is commonly observed in areas of primary tumours and of metastases, influences response to
treatment. However, its characterisation has so far mainly been restricted to the ex vivo analysis of tumour sections using monoclonal
antibodies specific to carbonic anhydrase IX (CA IX) or by pimonidazole staining, after the intravenous administration of this
2-nitroimidazole compound in experimental animal models.
METHODS: In this study, we describe the generation of high-affinity human monoclonal antibodies (A3 and CC7) specific to human CA
IX, using phage technology.
RESULTS: These antibodies were able to stain CA IX ex vivo and to target the cognate antigen in vivo. In one of the two animal models
of colorectal cancer studied (LS174T), CA IX imaging closely matched pimonidazole staining, with a preferential staining of tumour
areas characterised by little vascularity and low perfusion. In contrast, in a second animal model (SW1222), distinct staining patterns
were observed for pimonidazole and CA IX targeting. We observed a complementary pattern of tumour regions targeted in vivo by
the clinical-stage vascular-targeting antibody L19 and the anti-CA IX antibody A3, indicating that a homogenous pattern of in vivo
tumour targeting could be achieved by a combination of the two antibodies.
CONCLUSION: The new human anti-CA IX antibodies are expected to be non-immunogenic in patients with cancer and may serve as
broadly applicable reagents for the non-invasive imaging of hypoxia and for pharmacodelivery applications.
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Monoclonal antibodies and their derivatives are increasingly being
used in anticancer therapeutic strategies for the selective delivery
of bioactive agents (e.g., full immunoglobulins for Fc-mediated cell
killing, drugs with cleavable linkers, radionuclides, photosensiti-
zers, pro-coagulant factors, cytokines) to the tumour environment,
thus sparing normal tissues (Payne, 2003; Adams and Weiner,
2005; Neri and Bicknell, 2005; Carter, 2006; Schrama et al, 2006;
Schliemann and Neri, 2007; Carter and Senter, 2008). Although
originally monoclonal antibodies specific to membrane antigens
on cancer cells have been used for tumour targeting applications,
alternative targets such as markers of angiogenesis (Schnitzer,
1998; Thorpe, 2004; Neri and Bicknell, 2005), stromal antigens
(Hofheinz et al, 2003; Rybak et al, 2007; Schliemann and Neri,
2007) and intracellular proteins released at sites of necrosis (Miller
et al, 1993; Street et al, 2006) are increasingly being considered. In
all these cases, antibody-mediated pharmacodelivery options are
particularly attractive in consideration of the fact that most
conventional cytotoxic agents and many therapeutic proteins
exhibit a reduced uptake at the tumour site, compared to normal
organs (Bosslet et al, 1998; Tarli et al, 1999). Human or humanised
monoclonal antibodies are preferred for targeting applications, as
they are less immunogenic compared with rodent or chimeric
antibodies (Hale et al, 1988; Winter et al, 1994).
Solid tumours are heterogenous masses and the characterisation
of the different microenvironments within a neoplastic lesion
provides information about the tumour structures, which can be
targeted in vivo with intravenously (i.v.) administered monoclonal
antibodies to induce a therapeutic response. In this context, the
characterisation of hypoxic regions within solid tumour masses
assumes a particular relevance, because hypoxic cancer cells are
less sensitive to certain killing agents (e.g., radiation and cytotoxic
compounds; (Weinmann et al, 2004; Bertout et al, 2008)). Hypoxic
regions in tumours of experimental animal models can be assessed
post-mortem by analysis of tissue sections, following i.v. admin-
istration of pimonidazole, a 2-nitroimidazole compound, which
is selectively reduced and binds to intracellular macromolecules
in hypoxic regions at pO2 o 10mmHg (Dearling et al, 2004).
However, it would be desirable to complement this invasive
procedure with a molecular imaging approach based on selective
ligands to accessible proteins overexpressed at sites of hypoxia.
Based on transcriptomic profiling of cells exposed to different
oxygen concentrations, our group and others had recognised that
carbonic anhydrase IX (CA IX) is one of the most overexpressed
genes in hypoxic conditions (Staller et al, 2003; Scheurer et al,
2004). In parallel, ex vivo staining of tumour sections with
monoclonal antibodies specific to CA IX had revealed staining
patterns overlapping (though somewhat broader) with the
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sneoplastic regions stained with pimonidazole (Olive et al, 2001;
Hoskin et al, 2003; Sobhanifar et al, 2005; Jankovic et al, 2006; Li
et al, 2007).
The functional contribution of CA IX to tumour growth and
progression has long been debated (Pouyssegur et al, 2006;
Brahimi-Horn et al, 2007). Very recently, Pouyssegur and
coworkers have reported that the simultaneous invalidation of
CA IX and CA XII using short hairpin RNA technology led to a
substantial growth retardation in transfected LS174T colorectal
cancer xenograft models, whereas the individual knock-
outs yielded a substantially lower tumour growth retardation
(Chiche et al, 2009).
Monoclonal antibodies have also been used to achieve a selective
in vivo localisation on cells, which display a high constitutive
expression of CA IX (van Dijk et al, 1991; Chrastina et al, 2003a,
2003b; Brouwers et al, 2004; van Schaijk et al, 2005), especially
kidney cancer cells, in which mutations in the gene encoding the
von Hippel-Lindau tumour suppressor (pVHL) lead to a
constitutive HIF-1a activation and, as a consequence, to a strong
upregulation of CA IX on all tumour cells (Wykoff et al, 2000;
Mazure et al, 2004). This target was also detected as one of the
most prominent accessible markers of renal cell carcinoma (RCC)
in a chemical proteomic study, based on the ex vivo perfusion of
surgically resected human kidneys with cancer using an active
ester derivative of biotin, followed by capture of biotinylated
proteins and mass spectrometric analysis (Castronovo et al, 2006).
Although hypoxic areas can be efficiently stained with CA IX
antibodies ex vivo, at the beginning of this study, it was not known
whether the same structures could be targeted in vivo, considering
that they are typically located at a 100–200mm distance from the
nearest tumour blood vessel (Kerbel and Folkman, 2002) and thus
may be more difficult to reach. Indeed, although the antibody-
based targeting of markers of tumour neo-vasculature is a rapid
and efficient process (e.g., L19 antibody specific to the alternatively
spliced EDB domain of fibronectin; (Tarli et al, 1999; Viti et al,
1999; Borsi et al, 2002, 2003; Berndorff et al, 2005; Tijink et al,
2006)), the tissue penetration of monoclonal antibodies to certain
albuminal structures is often impaired by several factors, including
molecular size (Yokota et al, 1992; Adams et al, 1998; Low et al,
2008), antigen barrier (Dennis et al, 2007; El-Emir et al, 2007b),
and tumour interstitial pressure (Jain, 1987). In this article, we
describe the generation and characterisation of two high-affinity
human monoclonal antibodies (A3 and CC7) specific to the
extracellular carbonic anhydrase (CA) domain of human CA IX.
Both antibodies were shown to selectively recognise CA IX on the
surface of tumour cells in vitro, in tumour sections ex vivo and to
preferentially localise at sites of hypoxia in vivo following i.v.
administration.
MATERIALS AND METHODS
Cell lines
Cell culture media and supplements were purchased from
Invitrogen (Basel, Switzerland).
The human colorectal adenocarcinoma cell lines LS174T (CL-
188, ATCC) and HT-29 (HTB-38, ATCC) were maintained in
DMEM and McCoy’s 5A medium, respectively, supplemented with
10% fetal bovine serum (FBS) and antibiotic–antimycotic at 371C
in an atmosphere of 5% CO2. The human glioblastoma cell line
U87 (HTB-14, ATCC) was cultured in MEM medium, supplemen-
ted as described above. The human RCC cell line SK-RC-52 (Ebert
et al, 1990), a kind gift of Professor E Oosterwijk, was cultured in
RPMI medium, supplemented as described above. The human
colorectal adenocarcinoma cell line SW1222 was maintained in
MEM medium supplemented with 10% FBS, 1% glutamine and 1%
non-essential amino acids.
Cloning, expression, and purification of recombinant
human CA IX
T h ec D N Af r a g m e n te n c o d i n gt h ec a r b o n i ca n h y d r a s e( C A )
extracellular domain (aa 120–397) of CA IX was amplified from
the full-length cDNA clone IRAUp969G1273D (imaGenes, Berlin,
Germany) used as template with primers BW_CA9 (50-GGAGATCC
TCAAGAACCCCA-30) and FW_CA9_6xHis (50-TTCCTCGAGTTA
GTGATGGTGATGGTGATGACTGCTGTCCACTCCAGCAG-30)i n t r o -
ducing a C-terminal 6xHis-tag. A secretion sequence, required for
secretion into the extracellular medium, was amplified from the
construct SIP(L19)-pcDNA3.1 (Borsi et al, 2002) using BW_SIP (50-G
ATAAGCTTGTCGACCATGGGCTGGAG-30) and FW_SIP (50-TGG
GGTTCTTGAGGATCTCCCGAGTGCACACCTGTGGAGA-30) primers.
The resulting PCR fragments were gel-purified, assembled by PCR
and cloned into vector pCEP4 (Invitrogen) by means of HindIII
and XhoI digestion. The sequence-verified plasmid was used to
transfect HEK 293 EBNA cell line using FuGENE 6 transfection
reagent (Roche, Basel, Switzerland). Transiently transfected cells
were cultured in DMEM supplemented with 10% FBS and selected
using 200mgml
–1 of hygromycin (Invitrogen). The recombinant
domain of CA IX was purified from supernatant by affinity
chromatography on Ni-NTA agarose (Qiagen, Hombrechtikon,
Switzerland) by means of the C-terminal 6xHis-tag. The purified
protein was analysed by SDS–PAGE, size-exclusion chromatogra-
phy using a Superdex 200 HR 10/30 column (GE Healthcare,
Otelfingen, Switzerland). The specific activity of 1mg recombinant
protein was measured at 400nm by its esterase activity as a
surrogate of carbondioxide hydration activity (Pocker and Stone,
1967), using 1mM 4-nitrophenyl acetate as substrate in 100ml
50mM Tris/SO4
2  pH 8.5. For biotinylation of recombinant CA IX
EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL, USA) was
used according to the manufacturer’s instructions.
Selections of antibodies from the ETH-2-Gold library
Selections of antibodies were carried out on Immunotubes (Nunc,
Roskilde, Denmark) coated with recombinant CA IX at 50mgml
–1
in PBS (20mM NaH2PO4,3 0m M Na2HPO4, 100mM NaCl, pH 7.4),
as described previously by our group (Silacci et al, 2005).
Recombinant antibody fragments, which were positive in ELISA,
in the scFv format were expressed in E.coli TG-1 and purified from
culture supernatant by affinity chromatography using Protein A
Sepharose Fast Flow resin (GE Healthcare), as described previously
(Silacci et al, 2005).
Purified antibody fragments were analysed by SDS–PAGE and
by size-exclusion chromatography on a Superdex 75 HR 10/30
column (GE Healthcare).
Construction of the affinity maturation libraries and
selections of antibodies
The first affinity maturation library of scFv(A11) was cloned by
introducing sequence variability in the CDR1 loops of both heavy and
light chain. Antibody residues are numbered according to (Tomlinson
et al, 1992) and (Williams et al, 1996). Mutations at positions 31, 32,
33 of VH and 31, 31a, 32 of VL were introduced by PCR using the
same partially degenerate primers (Eurofins MWG Operon, Ebersberg,
Germany) as describedp r e v i o u s l y( V i l l aet al, 2008). A single round of
selection on biotinylated antigen (final concentration 10
 7 M) was
carried out eluting bound phage with 100mM triethylamine, as
described previously (Silacci et al, 2005). ELISA and Biacore
(Otelfingen, Switzerland) screening of dissociation profiles of selected
clones on a high-density coated chip yielded the antibody A3.
In the construction of the second affinity maturation library,
scFv(A3) was used as template. Sequence variability was intro-
duced in the CDR2 loops of both heavy and light chain. Mutations
at positions 52, 52a, 53, and 56 of VH and at positions 50. Positions
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s52 and 53 of VL were introduced using partially degenerate primers
(Eurofins MWG Operon), as described by (Silacci et al,2 0 0 6 ) .A
single round of selection on biotinylated antigen followed by a
screening procedure, as described above, yielded the antibody CC7.
Biacore analysis
Affinity measurements were performed on a Biacore 3000
instrument (Biacore). 555 RU biotinylated recombinant CA IX
were immobilised onto a streptavidin SA chip (Biacore). For the
real-time interaction analysis peaks representing the monomeric
fractions of scFv(A3) and scFv(CC7) were collected by size-
exclusion on a Superdex 75 HR 10/30 column (GE Healthcare) and
injected at a flow of 20mlmin
–1on the low-density coated antigen
chip. All kinetic data were evaluated using the BIAevaluation 4.1
software (Biacore).
Cloning, expression, and purification of antibodies in the
SIP format
ScFvs were converted into the SIP format by cloning VH and VL
into pcDNA3.1 (Invitrogen) using the same primers and strategy as
described by (Silacci et al, 2006) (Figure 1). The plasmids were
transfected into CHO-S cells (Invitrogen) using Cell Line
Nucleofector Kit V (Amaxa, Ko ¨ln, Germany), following the
manufacturer’s protocol. Transfectomas were grown in RPMI
supplemented with 10% FBS and selected by addition of
500mgml
–1 Geneticin (G418) (Merck Chemicals Ltd, Nottingham,
UK). Monoclonal cultures were obtained by fluorescent-activated
cell sorting after staining for secreted antibody, as described
(Zuberbu ¨hler et al, 2008). After 14 days of selection, cells were
brought into suspension, and cultured in Power CHO-CD 2
(Lonza, Basel, Switzerland). SIP antibodies were purified from
culture medium by affinity chromatography using Protein A
Sepharose Fast Flow resin (GE Healthcare), as described by
(Zuberbu ¨hler et al, 2008).
Fluorescence-activated cell sorting
Cells were harvested through incubation with 10mM EDTA in PBS
for 3min at 371C. After counting and a centrifugation step of 5min
at 1100r.p.m., cells were re-suspended in PBS supplemented
with 2% FBS to a final concentration of 5 10
6 cells per ml. Cells
(1 10
6) were then incubated for 30min at room temperature with
1mgml
–1of SIP(A3) and SIP(CC7), respectively, in the presence of
2% FBS. For the detection, rabbit-anti-human IgE antibody (Dako,
Glostrup, Denmark), followed by goat anti-rabbit IgG Alexa Fluor
488 antibody (Invitrogen) were used, diluted according to the
manufacturer’s recommendation. Rinsing with PBS was performed
in between the incubation steps. Fluorescence-activated cell
sorting (FACS) was performed on a FACSCanto equipped with
FACSDiva software (BD Biosciences, Allschwil, Switzerland). A
typical cell area was gated and a total of 10000 events per sample
were acquired. Omission of the primary antibody, as well as an
isotype-matched control anti-lysozyme antibody, SIP(HyHEL-10)
(Lavoie et al, 1992), at 9mgml
–1 were used to define background
staining. Results were expressed in percentage of the maximal
FACS signal. Data were analysed using FloJo software (Tree Star,
Olten, Switzerland).
Immunofluorescence on frozen tissue sections
Healthy and tumour tissue was embedded in freezing medium
(Microm, Volketswil, Switzerland), snap frozen in liquid nitrogen
a n ds t o r e da t 801C until sectioned. Tissue sections (10mm) were
first fixed for 10min in ice-cold acetone, rehydrated with PBS,
blocked with FBS and then double-stained for CA IX and CD31.
SIP(A3) and SIP(CC7), used as primary binding reagents at 1mgml
–1,
were detected with rabbit-anti-human IgE antibody (Dako),
followed by goat anti-rabbit IgG Alexa Fluor 594 antibody
(Invitrogen). Primary rabbit polyclonal anti-CA IX antiserum
(sc-25599; Santa Cruz Biotechnology, Heidelberg, Germany) was
detected with goat anti-rabbit IgG Alexa Fluor 594 antibody
scFv
Ncol G4SG4SG4 Notl amber
pelB VH VL myc-
tag pIII
pHEN1
HindIII
SS VH VL εCH4
EcoRI G4SG4SG4
SIP
SG
pcDNA3.1
scFV
VH VL
scFV(A3) scFV(CC7)
R NR RN R kDa
250
130
100
70
55
35
27
15
10
SIP(A3) SIP(CC7)
RN RRN R kDa
250
SIP
VH
VL VL
VH
CH4 CH4
130
100
70
55
35
27
15
10
Figure 1 Cloning, purification and quality control of anti-CA IX antibodies. (A) The ETH-2-Gold phage antibody library (Silacci et al, 2005) was cloned
into pHEN1 vector with VH and VL segments of scFvs flanked by the pelB secretion sequence, and an myc-tag followed by an amber codon and the gene-
encoding pIII. (B, E) Schematic representation of the different antibody formats used in this study. ScFv fragments consist of a variable heavy (VH) and a
variable light (VL) chain connected by a peptide linker, whereas the small immunoprotein (SIP) (Borsi et al, 2002) is a disulfide-linked homodimer of two
scFv–eCH4 fusions (C, F) SDS–PAGE analysis of the purified scFv(A3), scFv(CC7) and SIP(A3) and SIP(CC7), respectively, under reducing (R) and non-
reducing (NR) conditions. (D) Cloning strategy for the SIP antibodies.
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s(Invitrogen). Primary rat anti-mouse CD31 antibody (BD Biosciences)
was detected with donkey anti-rat IgG Alexa Fluor 488 antibody
(Invitrogen). All commercial binding reagents were diluted
according to the manufacturer’s recommendation. Rinsing with
PBS was performed in between all incubation steps. Finally, slides
were mounted with Glycergel mounting medium (Dako) and
analysed with a Zeiss Axioskop 2 mot fluorescence microscope
(Carl Zeiss AG, Feldbach, Switzerland). Images were captured with
an AxioCam MRC using AxioVision 4.7 image analysis software
(Carl Zeiss AG).
Multi-fluorescence microscopy
LS174T or SW1222 human colorectal adenocarcinoma cells
(5 10
6) were injected s.c. into the left flank of 6- to 8-week-old
female MF1 nu/nu mice. Tumours were allowed to grow for 14
days to a size of typically 1–1.5cm
3.
All mice were injected i.v. into the tail vein with 100mgo f
SIP(A3) (n¼3) or SIP(CC7) (n¼3) 6h before killing. To relate
anti-CAIX SIP antibody distribution to tumour morphology/
pathophysiology, the following parameters were studied by
multi-fluorescence microscopy: (i) perfusion: the in vivo DNA-
binding dye Hoechst 33342 (10mgkg
 1; Invitrogen) was injected
i.v. 1min before killing. (ii) Blood vessels: an anti-CD31 antibody
was used to stain for blood vessel distribution. (iii) Hypoxia:
the hypoxic cell marker pimonidazole hydrochloride (1-[(2-
hydroxy-3-piperidinyl) propyl]-2-nitroimidazole hydrochloride;
60mgkg
 1; Natural Pharmacia International Inc., Burlington,
MA, USA) was injected 30min before killing.
Sections (12mm) were first fixed in acetone for 10min at room
temperature and blocked for 20mins with 3% normal goat serum
(Dako). Three serial sections from the same tumour were
incubated with a 1:2 dilution of rat anti-mouse CD31 simulta-
neously with one of the following antibodies: (1) 1:200 dilution of
rabbit anti-pimonidazole (Natural Pharmacia International Inc.),
(2) 1:1000 dilution of rabbit anti-human IgE (Dako; to detect the
injected SIP(A3) and SIP(CC7)) or (3) 1:10 dilution of rabbit
polyclonal anti-CAIX antiserum (sc-25599; Santa Cruz). After
rinsing with PBS, sections were incubated with a 1:200 dilution of
goat anti-rat Alexa Fluor 594 antibody and goat anti-rabbit IgG
Alexa Fluor 488 (Invitrogen). Sections were mounted in PBS and
viewed using an AxioImager.Z1 microscope (Carl Zeiss AG), fitted
with a computer-controlled motorised stage. Images were captured
by an AxioCam digital black and white camera using AxioVision
4.6 image analysis software (Carl Zeiss AG). Image processing was
performed as described previously (El-Emir et al, 2007b).
Biodistribution in LS174T human colorectal carcinoma
model
LS174T human colorectal adenocarcinoma cells (1 10
7)w e r e
injected s.c. into the left flank of 6- to 8-week-old female Balb/c nu/
nu mice (Charles River, Sulzfeld, Germany). Tumours were allowed to
grow for 15 days to a weight of typically 200mg. SIP(A3), SIP(CC7),
SIP(HyHEL-10) and SIP(L19) were conjugated to p-isothiocyanato-
benzyl-diethylene triamine pentaacetic acid (p-SCN-Bn-DTPA;
Macrocyclics) in 0.1 M NaHCO3 b u f f e ra tp H8 . 2b yi n c u b a t i o nw i t h
a 50-fold molar excess of p-SCN-Bn-DTPA for 1h at room
temperature. The p-SCN-Bn-DTPA-SIP conjugates were purified by
size-exclusion on a PD-10 column (GE Healthcare). Mass spectro-
metric analysis revealed B1.8 modifications/antibody molecule.
The p-SCN-Bn-DTPA-SIP conjugates were labelled with
177Lu (Perkin Elmer, Schwerzenbach, Switzerland) in a 125mM
ammonium acetate buffer pH 5.5 for 1h at room temperature, as
described by (Brouwers et al, 2004). Subsequently, free
177Lu was
complexed by addition of 2.5mM EDTA. The radiolabelled
antibody preparation was purified by size-exclusion on a PD-10
column (GE Healthcare) and eluted with PBS. For all preparations,
the rate of radiolabel incorporation and the immunoreactivity were
determined, as described (Tarli et al, 1999). The in vivo targeting
performance of the
177Lu-labelled antibody preparations was
evaluated by i.v. injection of 6–11mg per mouse (7–11mCi) in
200ml into the tail vein of xenograft-bearing nude mice. Each group
contained four individuals. Mice were killed 24h after injection.
Organs were excised, weighed and the radioactivity was counted.
Targeting results are expressed as both tumour/organ ratios and as
percentage of injected dose per gram of tissue (% IDg
 1).
All in vivo studies were carried out according to Swiss
regulations under a project license granted by the Veterina ¨ramt
des Kantons Zu ¨rich (198/2005)
RESULTS
Isolation of A3 and CC7, two human monoclonal
antibodies specific to CA IX
The CA domain of CA IX (residues 120–397) was cloned and
expressed as soluble protein in HEK EBNA 293 cells (Figure 2A)
and purified from the cell culture supernatant on Ni-NTA resin by
means of a C-terminal 6xHis-tag. The native structure of CA IX on
the cell membrane is reported to consist of cysteine-linked trimers
(Pastorekova et al, 1992; Thiry et al, 2006). We observed the
formation of a covalent homodimer (B75%) and of a monomeric
protein (B25%) both by SDS–PAGE analysis (Figure 2B) and
by size-exclusion chromatography (Figure 2C). The specific
esterase activity of the purified protein, as measured with 1mM
4-nitrophenylacetate and 1.6mg recombinant enzyme in 100mlo f
50mM Tris-SO4,p H¼8.5 containing 10mM ZnSO4 at 400nm, was
determined to be 1nmolmin
 1mg
 1 (Figure 2D). This suggests
that the enzyme is also catalytically active in terms of carbon-
dioxide hydration.
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Figure 2 Cloning, purification and quality control of recombinant CA IX.
(A) Residues 120–397 corresponding to the extracellular CA domain of
CA IX, flanked by a secretion sequence (SS) and a C-terminal 6xHis-tag,
were cloned into pCEP4. (B) SDS–PAGE analysis of the purified
recombinant CA IX. Under non-reducing (NR) conditions the protein
mainly forms a covalent homodimer (d), whereas under reducing (R)
conditions the monomeric protein (m) with a molecular weight of 31.2kDa
can be observed. (C) Size-exclusion chromatography of the purified
recombinant CA IX. The retention volume (ml) of the major peak
corresponds to a covalently formed homodimer (d). (D) The specific
activity of the recombinant protein was measured at 400nm by its esterase
activity, using 1mM 4-Nitrophenyl acetate as substrate (solid line).
Spontaneous hydrolysis of the substrate is reported as dashed line.
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sThe recombinant catalytic domain of CA IX was used for the
isolation of human monoclonal antibodies from the ETH-2-Gold
phage antibody library (Silacci et al, 2005). One of the clones
isolated from the library (‘A11’) (Table 1), which was shown to be
non-inhibitory in the enzymatic assay described above (data not
shown), was affinity-matured by combinatorial mutagenesis of
residues in the CDR1 loops of VH and VL domains according to a
procedure recently developed by our group (Villa et al, 2008),
yielding clone A3. Additional mutagenesis of CDR2 loops led to the
isolation of the daughter antibody clone CC7 (Table 1). The A3 and
CC7 antibodies were expressed as scFv fragment in E.coli and in
small immunoprotein (SIP) format in CHO-S cells using published
procedures (Borsi et al, 2002) and purified to homogeneity by
protein A affinity chromatography (Figure 1). The scFv format is
particularly suitable for affinity determination using Biacore
technology, whereas the homobivalent SIP format has been shown
to offer distinctive advantages for in vivo molecular imaging
applications (Borsi et al, 2002; Berndorff et al, 2005; Olafsen et al,
2005; Tijink et al, 2006; von Lukowicz et al, 2007; Sauer et al, 2009).
In vitro characterisation of A3 and CC7 antibodies
The monomeric fractions of the A3 and CC7 antibodies in
recombinant scFv format were isolated by size-exclusion chroma-
tography and analysed by real-time interaction analysis on a
Biacore instrument, using a microsensor chip coated with the
recombinant CA domain of CA IX. Figure 3 illustrates sensograms
for the two antibodies, revealing a Kd dissociation constant of
2.4nM for scFv(A3) [kon¼9.1 10
5 s
 1M
 1; koff¼2.2 10
 3 s
 1]
and of 3.2nM for scFv(CC7) [kon¼4.3 10
5 s
 1M
 1;
koff¼1.4 10
 3 s
 1].
The ability of the two antibodies in SIP format to recognise the
native CA IX on the surface of tumour cells was investigated by
fluorescence-activated cell sorting (FACS), in comparison to a
recombinant SIP antibody of irrelevant specificity (HyHEL-10;
(Lavoie et al, 1992). Figure 4 shows that a partial shift in the FACS
profile was observed for the colorectal cancer cell line LS174T,
whereas a very marked increase of cell fluorescence was detected
for the pVHL-defective human RCC cell line SK-RC-52, similar to
what previously reported for the clinical-stage cG250 monoclonal
antibody (Grabmaier et al, 2000).
A3 and CC7 were then tested by immunofluorescence for their
ability to detect CA IX in a panel of xenografted human tumour
tissue sections. Figure 5 shows the staining obtained with A3 only,
because both antibodies performed equally well. As positive
control, a commercial polyclonal anti-CA IX antiserum was used.
A representative positive and negative control is shown for the
LS174T tumour. A strong CA IX staining (green) was detectable in
the colorectal cancer models LS174T and HT-29 at a distance of
B100mm from tumour blood vessels (red). In contrast, virtually
all tumour cells in SW 1222 colorectal carcinoma, U87 glioma, and
in SK-RC-52 renal cell carcinomas exhibited a strongly positive CA
IX staining. However, although SW 1222 and U87 exhibited a
defined vascular structure, CD31 staining in SK-RC-52 tumours
yielded an irregular staining network. Other cancer types displayed
a weaker level of CA IX staining (e.g., NCI-H460 human non-small
cell lung carcinoma), whereas MCF-7 breast tumours and Ramos
lymphomas were essentially negative (data not shown).
A3 and CC7 selectively target hypoxic tumour regions
in vivo
To investigate whether the new human anti-CA IX antibodies were
able to selectively localise to the antigen in tumours, following i.v.
administration in the tail vein, we used both fluorescence
microscopy and radioactivity-based detection methods. As mouse
models of human cancer, we chose LS174T and SW1222 tumours:
two colorectal cancer models, which have previously been
extensively studied using monoclonal antibodies specific to the
carcinoembryonic antigen (El Emir et al, 2007a; Fidarova et al,
2008) and with the vascular-targeting anti-EDB antibody L19
(El-Emir et al, 2007b).
Figure 6 shows representative results of a multi-colour
fluorescence microscopy analysis of serial sections from LS174T
tumours, following i.v. administration of SIP(A3) (6h before
killing of the mice), of pimonidazole (30min before killing) and
Hoechst 33342 (1min before killing). The low magnification
images (top panels) yield an informative impression of the
heterogeneity of these tumours. One can recognise areas with
dense vascular structures (red), some of which are well perfused
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Figure 3 Biacore analysis of purified monomeric scFv preparations
injected at different concentrations. (A) Binding of scFv(A3) and
(B) scFv(CC7) to the extracellular CA domain of CA IX. Kinetic constants
were calculated with the BIA evaluation 4.1 software.
Table 1 Relevant amino acid positions of antibody clones isolated from
the designed synthetic libraries
VH chain VL chain
ScFv 31–33
a 52–56
a 95–100
a 31–32
a 50–53
a 91–96
a
A 1 1 SYA SGSGGS GKWRTD SYY GKNN PRGGRD
A3 WYA SGSGGS GKWRTD RHL GKNN PRGGRD
CC7 WYA AGTGGH GKWRTD RHL GKNN PRGGRD
Positions that are mutated in the primary antibody library (ETH-2-Gold) are
underlined. Residues in A3 and CC7, mutated during the affinity maturation
procedure, are in boldface. CC7 revealed an additional mutation (R instead of K) at
position 39 in the VL chain sequence. Single amino acid codes are used according to
standard IUPAC nomenclature.
aNumbering according to (Tomlinson et al, 1992)
and (Williams et al, 1996).
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s(blue). The structures targeted in vivo by SIP(A3) closely match
those stained ex vivo for pimonidazole modification, confirming
that these hypoxic areas could be reached by the i.v. administered
antibody. Importantly, these areas are superimposable to the
structures stained ex vivo with a polyclonal anti-CA IX antiserum,
thus indicating that CA IX-positive areas of the tumour could be
reached by our reagent. A higher magnification view (bottom
panels) shows details of well perfused areas with no detectable CA
IX expression, as well as tumour regions efficiently targeted by the
A3 antibody. Similar results were obtained with SIP(CC7)
(Supplementary Figure).
The selective tumour targeting of the human anti-CA IX
antibodies was also evaluated by immunofluoresence, comparing
sections of tumours and of normal organs, 6h after i.v.
administration of SIP(A3). Figure 7 shows that a much brighter
fluorescence signal was observed in tumour lesions, compared
with normal organs (heart, intestine, kidney, liver, lung, and
spleen).
Figure 8 presents a similar analysis for the in vivo targeting of
SW1222 tumours. In this model, one can observe a striking
difference between external, well-perfused areas (blue) and
complementary, poorly perfused hypoxic regions in the tumour
core. Although an ex vivo analysis with the anti-CA IX antiserum
yields a pattern with uniform staining intensity, the regions
targeted in vivo by SIP(A3) mainly cluster around central vascular
structures, with a gradient of staining intensity (green) which
reflects a gradient in antibody diffusion. Interestingly, in this
tumour model, pimonidazole staining and CA IX staining do not
always overlap. Similar results were obtained with SIP(CC7)
(Supplementary Figure).
To assess the efficiency of in vivo targeting of CA IX, we
performed a comparative biodistribution analysis with SIP(A3),
SIP(HyHEL-10) used as negative control and SIP(L19), a clinical-
stage antibody which recognises tumour neo-vascular structures
(Borsi et al, 2002; Berndorff et al, 2005; Tijink et al, 2006; El-Emir
et al, 2007b; Sauer et al, 2009). We used antibody preparations
labelled with lutetium-177 rather than radioiodine, as previous
studies had suggested that anti-CA IX antibodies are deiodinated
upon internalisation (Brouwers et al, 2004). Table 2 presents
the biodistribution results for the three antibodies in LS174T
tumour-bearing mice, 24h after i.v. administration. Targeting data
are expressed both as tumour/organ ratios and percent
injected antibody dose per gram of tissue (% IDg
 1)±s.e.. At
this time point, SIP(L19) displayed a tumour accumulation of 9.3
%IDg
 1, with a tumour/blood ratio of 5.8. SIP(A3) exhibited a
lower tumour uptake (2.4 %IDg
 1), but a better tumour/blood
ratio (16.7). The negative control antibody displayed lower tumour
uptake (1.1 %IDg
 1), in line with previous studies (Tarli et al,
1999).
DISCUSSION
In this study, we describe the isolation of the first fully human
monoclonal antibodies (A3 and CC7) with high affinity to CA IX.
Furthermore, the in vivo distribution and tumour-targeting
properties of the two antibodies have been investigated using
both fluorescence-based techniques and radiolabelled antibody
preparations.
Monoclonal antibodies represent the most rapidly growing
sector of Pharmaceutical Biotechnology (Walsh, 2006), particularly
for cancer therapy applications. As antibodies recognise their
cognate antigens with exquisite selectivity, intense research efforts
are devoted to the exploitation of these binding specificities for the
development of superior therapeutic agents (Carter, 2006). As
rodent and chimeric antibodies are immunogenic in patients, there
SIP(A3) SIP(CC7) SIP(HyHEL-10)
SIP(HyHEL-10) SIP(CC7) SIP(A3)
01 0 2 103 104 105
FITC-A
100
80
60
40
20
0
P
e
r
c
e
n
t
a
g
e
 
o
f
 
m
a
x
i
m
a
l
 
F
A
C
S
 
s
i
g
n
a
l
P
e
r
c
e
n
t
a
g
e
 
o
f
 
m
a
x
i
m
a
l
 
F
A
C
S
 
s
i
g
n
a
l
P
e
r
c
e
n
t
a
g
e
 
o
f
 
m
a
x
i
m
a
l
 
F
A
C
S
 
s
i
g
n
a
l
P
e
r
c
e
n
t
a
g
e
 
o
f
 
m
a
x
i
m
a
l
 
F
A
C
S
 
s
i
g
n
a
l
P
e
r
c
e
n
t
a
g
e
 
o
f
 
m
a
x
i
m
a
l
 
F
A
C
S
 
s
i
g
n
a
l
P
e
r
c
e
n
t
a
g
e
 
o
f
 
m
a
x
i
m
a
l
 
F
A
C
S
 
s
i
g
n
a
l
01 0 2 103 104 105
FITC-A
100
80
60
40
20
0
01 0 2 103 104 105
FITC-A
100
80
60
40
20
0
01 0 2 103 104 105
FITC-A
100
80
60
40
20
0
01 0 2 103 104 105
FITC-A
100
80
60
40
20
0
01 0 2 103 104 105
FITC-A
100
80
60
40
20
0
L
S
1
7
4
T
S
K
-
R
C
-
5
2
Figure 4 CA IX FACS histogram plots of two different human tumour cell lines. (A–C) Open curves indicate FACS histogram plots of LS174T human
colorectal adenocarcinoma cells stained with SIP(A3), SIP(CC7) (both at 1mgml
 1) or the isotype-matched control SIP(HyHEL-10) (at 9mgml
 1), detected
as described before. Solid curves represent FACS histogram plots of LS174T cells where the primary antibody was omitted for detection. (D–E) Open and
solid curves indicate FACS histogram plots of SK-RC-52 human RCC cells stained as described for A–C.
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Figure 5 Immunofluorescence analysis performed on (A–C, P–U) human colorectal adenocarcinoma LS174T, (D–F) human colorectal
adenomacarcinoma SW1222, (G–I) human colorectal adenocarcinoma HT-29, (J–L) human glioblastoma U87 and (M–O) human RCC SK-RC-52
xenografted tumour tissue sections. Red staining in the left panels represents endothelial cells (anti-CD31 staining), whereas green staining in the middle
panels represents expression of CA IX ((B, E, H, K, N) SIP(A3) or (T) polyclonal anti-CA IX antiserum staining). Overlay of red and green fluorescence is
shown in the panels to the right. (Q) Primary antibody was omitted as a negative control. Scale bar¼100mm.
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sis an increased need for good quality human monoclonal antibodies,
which can be used for imaging and therapeutic purposes (Winter
and Harris, 1993; Pendley et al, 2003; Presta, 2006). Both A3 and
CC7 are fully human antibodies, which recognise human CAIX in its
native conformation with affinities in the low nanomolar range.
Interestingly, it was necessary to express the recombinant antigen in
a mammalian system, as previous attempts to generate anti-CA IX
antibodies from bacterially produced catalytic domain led to the
isolation of antibody clones, which did not recognise the antigen in
its native conformation (data not shown). With the newly reported
A3 and CC7 antibodies CA IX was shown to be expressed
heterogeneously throughout the majority of the studied tumours,
with exception of renal cell carcinomas in which all cancer cells
express the antigen as a consequence of a mutated VHL gene
(Rathmell and Chen, 2008) (Figure 5). The hypoxia-related CA IX
expression was usually detectable at a distance4100mmf r o mt h e
nearest oxygen-supplying blood vessel. This finding is in agreement
with previous reports (Hockel et al,1 9 9 6 ;W y k o f fet al, 2000, 2001;
Beasley et al, 2001; Koukourakis et al, 2001; Loncaster et al,2 0 0 1 )
and in accordance with the diffusion limit of oxygen within tissues,
which has been measured to be around 150mm (Folkman et al, 2000;
Vaupel, 2004).
The A3 and CC7 antibodies do not inhibit CA IX activity and do
not bind to CA XII, which is upregulated along with CA IX under
hypoxic conditions and which shares only 39% sequence identity
with CA IX. In general, the choice of non-inhibitory antibodies
represents a useful general precaution for antibodies specific to
targets (e.g., matrix metalloproteinases), where endogenous
inhibitors may compromise in vivo localisation performance of
the antibody. To implement biomedical strategies aimed at the
simultaneous inhibition of CA IX and CA XII activities Chiche
et al, 2009 (Cancer Res., 69, 358–368), the use membrane-
impermeable sulfonamides, which display inhibitory constants in
the low nanomolar range both towards CA IX and CA XII may be
preferable (Svastova ´ et al, 2004; Cecchi et al., 2005; Dubois et al,
2007; Supuran, 2008; Ahlskog et al, 2009).
By multi-fluorescence microscopy we subsequently demon-
strated that the A3 and CC7 antibodies, in recombinant SIP format,
preferentially localised to hypoxic areas of LS174T and SW1222
colorectal tumour xenografts 6h after i.v. administration. The
Pimonidazole SIP(A3) (in vivo) Anti-CA IX (ex vivo)
Figure 6 Multi-fluorescence microscopy analysis in LS174T xenograft-bearing mice. (A,B) Representative overlays of multiple digital fluorescence images
of a LS174T tumour injected with pimonidazole (30min before killing) and SIP(A3) (6h before killing) demonstrating perfusion with Hoechst 33342 (1min
before killing) (blue), blood vessel staining (red), pimonidazole binding (green, left panel) and CA IX targeting by SIP(A3) (green, middle panel). (C) ex vivo
staining of an adjacent tumour section with a polyclonal anti-CA IX antiserum. (D–F) Higher magnification images of mainly perfused areas of the
corresponding tumour sections. (G–I) Higher magnification images of mainly CA IX-positive areas of the corresponding tumour sections. (A–C) Scale
bar¼500mm and (D–I) scale bar¼100mm. N indicates necrosis.
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stumour uptake was dramatically more efficient compared with
normal organs, which displayed minimal staining at the same time
point, using an immunofluorescence detection method (Figure 7).
In the LS174T model an excellent overlap was observed between
pimonidazole staining and structures targeted in vivo by the anti-
CA IX antibodies in all studied animals, although A3 and CC7
appeared to stain slightly closer to the vasculature than did the
pimonidazole. The targeted structures were furthermore super-
imposable to the staining pattern of an ex vivo applied
commercially available polyclonal anti-CA IX antiserum. In the
SW1222 model CA IX expression was consistently detected in a
much broader area with the A3 and CC7 antibodies compared with
the one covalently modified by pimonidazole (Figure 8 and
Supplementary Figure). In these tumours, both A3 and CC7
showed reduced accumulation compared with the ex vivo applied
commercial anti-CA IX antiserum, and were in close proximity to
both large and small vascular structures. This may indicate a
barrier preventing a homogenous targeting of antigen within the
tumour mass, although other tumour factors may also be involved.
Interestingly, these large vascular structures were only poorly
perfused with the Hoechst dye.
To our knowledge, this is the first study in which pimonidazole
staining, CA IX targeting (both in vivo and ex vivo) and perfusion
are simultaneously analysed. As the time points for the injection of
antibody, pimonidazole and Hoechst 33342 were different (6h,
30min and 1min before killing, respectively), we cannot exclude
that a transient occlusion of certain vascular structures took place
(Chaplin et al, 2006).
Limitations in antibody diffusion within solid tumour masses
have previously been reported for reagents used in the IgG format
(Adams and Weiner, 2005; Dennis et al, 2007; El Emir et al, 2007a),
mainly in relation to the so-called ‘antigen barrier’. In this study,
we have used antibodies in SIP format (Borsi et al, 2002; Villa et al,
2008), as this format and similar mini-antibody formats (Wu and
Olafsen, 2008) have extensively been shown to offer distinctive
advantages both for imaging applications (Leyton et al, 2009); von
Lukowicz et al, 2007; Wei et al, 2008) and for radioimmunotherapy
of cancer (Berndorff et al, 2005; Tijink et al, 2006; Kenanova et al,
2007; Sauer et al, 2009). Recent publications suggest that smaller
high-affinity ligands (MW o 2000Da) may enjoy a much more
rapid tissue distribution compared with antibodies and antibody
fragments (Low et al, 2008). High-affinity low-molecular weight
ligands to CA IX have been reported (Supuran, 2008) and it will be
interesting to compare their in vivo tumour targeting properties
with those of the human antibodies A3 and CC7 with a molecular
weight of 76kDa.
In our biodistribution studies we have used lutetium-177
as radionuclide, in light of previous reports indicating that
dehalogenation takes place with internalising anti-CA IX
antibodies (Brouwers et al, 2004). With this radiometal, we
observed high kidney and liver values (Table 2), similar to what
we had previously reported for the
177Lu-labelled L19 antibody in
SIP format (Tijink et al, 2006). In the pairwise comparison
presented in this article, L19 appeared to yield higher tumour
uptake values, yet at the expense of a slower blood clearance.
Tumour pre-targeting strategies could also be considered, as they
have yielded excellent tumour/organ ratios over a range of
time points after injection (van Schaijk et al, 2005). By contrast,
Fab and F(ab’)2 preparations of the same antibody did not
exhibit improved selectivity compared with the IgG format
(van Dijk et al, 1991).
Our group has developed and brought to clinical trials human
monoclonal antibody derivatives based on the L19 (Pini et al,1 9 9 8 ) ,
F8 (Villa et al, 2008) and F16 (Brack et al, 2006) antibodies, specific
to splice isoforms of fibronectin and of tenascin-C, respectively.
These antibodies display comparable in vivo biodistribution results
and can target a broad variety of tumours. However, their uptake
within the solid tumour mass is confined to the subendothelial
extracellular matrix (Demartis et al, 2001; Borsi et al, 2002; El-Emir
et al,2 0 0 7 b ;V i l l aet al, 2008). The human anti-CA IX antibodies
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Figure 7 In vivo immunofluorescence analysis in LS174T xenograft-bearing mice. (A) Endothelial cells of tumour blood vessels are shown in red (ex vivo
anti-CD31 staining). (B) Green fluorescence staining represents CA IX targeting in the tumour 6h after i.v. administration of SIP(A3) detected with
immunofluorescence techniques. (C) Overlay of red (blood vessels) and green (targeted CA IX) staining in the tumour. (D) Heart, (E) intestine, (F) kidney,
(G) liver, (H) lung and (I) spleen, when stained accordingly, showed a negligible uptake of SIP(A3). Scale bar¼100mm.
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sappear to target a similarly broad spectrum of cancers, yet with
a four-times lower tumour uptake and a broader tissue distri-
bution within the lesion. For this reason, one could envisage the
simultaneous use of vascular-targeting and hypoxia-targeting
antibodies for pharmacodelivery applications, to achieve a
more homogenous distribution to a therapeutic agent (e.g.,
cytotoxic drug; (Wu and Senter, 2005; Carter and Senter, 2008))
within the tumour mass.
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Table 2 Biodistribution experiments of
177Lu-labelled anti-CA IX
antibodies in nude mice bearing LS174T human colorectal adenocarcinoma
xenografts
SIP(A3) SIP(HyHEL-10) SIP(L19)
Organs
Tumour 1.0 (2.41±0.19) 1.0 (1.13±0.08) 1.0 (9.30±1.11)
Blood 16.7 (0.14±0.03) 12.5 (0.09±0.01) 5.8 (1.59±0.11)
Liver 0.2 (11.83±0.50) 0.1 (15.91±0.83) 0.6 (16.08±0.68)
Lung 2.4 (0.99±0.06) 1.1 (1.03±0.09) 4.0 (2.33±0.13)
Spleen 0.5 (5.20±0.50) 0.0 (28.54±7.12) 1.3 (6.95±0.35)
Heart 2.4 (0.99±0.07) 0.9 (1.27±0.07) 4.8 (1.93±0.05)
Kidney 0.0 (85.72±5.67) 0.1 (12.14±0.62) 0.5 (20.67±0.24)
Intestine 2.7 (0.88±0.02) 2.3 (0.49±0.04) 3.5 (2.68±0.27)
Tumour/organ ratios, at 24h after i.v. injection, are indicated in boldface. The
numbers in brackets correspond to the percent injected antibody dose per gram of
tissue (% ID/g)±s.e. Student’s t-test was applied to calculate significant differences.
The tumour uptake of SIP(A3) is significantly higher than the one of the anti-lysozyme
antibody SIP(HyHEL-10) (Po0.001).
Pimonidazole SIP(A3) (in vivo) Anti-CA IX (ex vivo)
Figure 8 Multi-fluorescence microscopy analysis in SW1222 xenograft-bearing mice. (A and B) Representative overlays of multiple digital fluorescence
images of a SW1222 tumour injected with pimonidazole (30min before killing) and SIP(A3) (6h before killing) demonstrating perfusion with Hoechst 33342
(1min before killing) (blue), blood vessel staining (red), pimonidazole binding (green, left panel) and CA IX targeting by SIP(A3) (green, middle panel). (C) ex
vivo staining of an adjacent tumour section with a polyclonal anti-CA IX antiserum. (D–F) Higher magnification images of mainly perfused areas of the
corresponding tumour sections. (G–I) Higher magnification images of mainly CA IX-positive areas of the corresponding tumour sections. (A–C) Scale
bar¼500mm and (D–I) scale bar¼100mm.
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giche, Milan, Italy).
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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